Moderna, Inc. (MRNA) is a Biotechnology company in the Healthcare sector, currently trading at $54.26. It has a SharesGrow Score of 42/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is MRNA = $36 (-34.3% upside).
Valuation: MRNA trades at a trailing Price-to-Earnings (P/E) of -7.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.25.
Financials: revenue is $1.9B, -52.4%/yr average growth. Net income is $2.8B (loss), growing at -37.1%/yr. Net profit margin is -145.2% (negative). Gross margin is 55.3% (-16.6 pp trend).
Balance sheet: total debt is $1.9B against $8.7B equity (Debt-to-Equity (D/E) ratio 0.22, conservative). Current ratio is 3.29 (strong liquidity). Debt-to-assets is 15.5%. Total assets: $12.3B.
Analyst outlook: 8 / 27 analysts rate MRNA as buy (30%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 63/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 100/100 (Pass), Moat 65/100 (Partial), Future 16/100 (Fail), Income 10/100 (Fail).
